Chapter 1. Asia Pacific Market
1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By End User
1.4.1 Large Pharmaceutical Companies
1.4.2 Small and Mid-Size Biotech Firms
1.4.3 Contract Research Organizations
1.4.4 Academic and Research Institutes
1.5 Segmentation By Deployment Mode
1.5.1 Cloud-Based
1.5.2 Hybrid
1.5.3 On-Premise
1.6 Segmentation By Application
1.6.1 Clinical-Trial Design and Recruitment
1.6.2 Drug Discovery and Lead Identification
1.6.3 Lead Optimization
1.6.4 Pharmacovigilance and Safety Monitoring
1.6.5 Pre-clinical Development
1.6.6 Manufacturing-Process Optimization
1.6.7 Other Application
1.7 Segmentation By Country
1.7.1 China
1.7.1.1 Segmentation By End User
1.7.1.1.1 Large Pharmaceutical Companies
1.7.1.1.2 Small and Mid-Size Biotech Firms
1.7.1.1.3 Contract Research Organizations
1.7.1.1.4 Academic and Research Institutes
1.7.1.2 Segmentation By Deployment Mode
1.7.1.2.1 Cloud-Based
1.7.1.2.2 Hybrid
1.7.1.2.3 On-Premise
1.7.1.3 Segmentation By Application
1.7.1.3.1 Clinical-Trial Design and Recruitment
1.7.1.3.2 Drug Discovery and Lead Identification
1.7.1.3.3 Lead Optimization
1.7.1.3.4 Pharmacovigilance and Safety Monitoring
1.7.1.3.5 Pre-clinical Development
1.7.1.3.6 Manufacturing-Process Optimization
1.7.1.3.7 Other Application
1.7.2 Japan
1.7.2.1 Segmentation By End User
1.7.2.1.1 Large Pharmaceutical Companies
1.7.2.1.2 Small and Mid-Size Biotech Firms
1.7.2.1.3 Contract Research Organizations
1.7.2.1.4 Academic and Research Institutes
1.7.2.2 Segmentation By Deployment Mode
1.7.2.2.1 Cloud-Based
1.7.2.2.2 Hybrid
1.7.2.2.3 On-Premise
1.7.2.3 Segmentation By Application
1.7.2.3.1 Clinical-Trial Design and Recruitment
1.7.2.3.2 Drug Discovery and Lead Identification
1.7.2.3.3 Lead Optimization
1.7.2.3.4 Pharmacovigilance and Safety Monitoring
1.7.2.3.5 Pre-clinical Development
1.7.2.3.6 Manufacturing-Process Optimization
1.7.2.3.7 Other Application
1.7.3 India
1.7.3.1 Segmentation By End User
1.7.3.1.1 Large Pharmaceutical Companies
1.7.3.1.2 Small and Mid-Size Biotech Firms
1.7.3.1.3 Contract Research Organizations
1.7.3.1.4 Academic and Research Institutes
1.7.3.2 Segmentation By Deployment Mode
1.7.3.2.1 Cloud-Based
1.7.3.2.2 Hybrid
1.7.3.2.3 On-Premise
1.7.3.3 Segmentation By Application
1.7.3.3.1 Clinical-Trial Design and Recruitment
1.7.3.3.2 Drug Discovery and Lead Identification
1.7.3.3.3 Lead Optimization
1.7.3.3.4 Pharmacovigilance and Safety Monitoring
1.7.3.3.5 Pre-clinical Development
1.7.3.3.6 Manufacturing-Process Optimization
1.7.3.3.7 Other Application
1.7.4 South Korea
1.7.4.1 Segmentation By End User
1.7.4.1.1 Large Pharmaceutical Companies
1.7.4.1.2 Small and Mid-Size Biotech Firms
1.7.4.1.3 Contract Research Organizations
1.7.4.1.4 Academic and Research Institutes
1.7.4.2 Segmentation By Deployment Mode
1.7.4.2.1 Cloud-Based
1.7.4.2.2 Hybrid
1.7.4.2.3 On-Premise
1.7.4.3 Segmentation By Application
1.7.4.3.1 Clinical-Trial Design and Recruitment
1.7.4.3.2 Drug Discovery and Lead Identification
1.7.4.3.3 Lead Optimization
1.7.4.3.4 Pharmacovigilance and Safety Monitoring
1.7.4.3.5 Pre-clinical Development
1.7.4.3.6 Manufacturing-Process Optimization
1.7.4.3.7 Other Application
1.7.5 Australia
1.7.5.1 Segmentation By End User
1.7.5.1.1 Large Pharmaceutical Companies
1.7.5.1.2 Small and Mid-Size Biotech Firms
1.7.5.1.3 Contract Research Organizations
1.7.5.1.4 Academic and Research Institutes
1.7.5.2 Segmentation By Deployment Mode
1.7.5.2.1 Cloud-Based
1.7.5.2.2 Hybrid
1.7.5.2.3 On-Premise
1.7.5.3 Segmentation By Application
1.7.5.3.1 Clinical-Trial Design and Recruitment
1.7.5.3.2 Drug Discovery and Lead Identification
1.7.5.3.3 Lead Optimization
1.7.5.3.4 Pharmacovigilance and Safety Monitoring
1.7.5.3.5 Pre-clinical Development
1.7.5.3.6 Manufacturing-Process Optimization
1.7.5.3.7 Other Application
1.7.6 Malaysia
1.7.6.1 Segmentation By End User
1.7.6.1.1 Large Pharmaceutical Companies
1.7.6.1.2 Small and Mid-Size Biotech Firms
1.7.6.1.3 Contract Research Organizations
1.7.6.1.4 Academic and Research Institutes
1.7.6.2 Segmentation By Deployment Mode
1.7.6.2.1 Cloud-Based
1.7.6.2.2 Hybrid
1.7.6.2.3 On-Premise
1.7.6.3 Segmentation By Application
1.7.6.3.1 Clinical-Trial Design and Recruitment
1.7.6.3.2 Drug Discovery and Lead Identification
1.7.6.3.3 Lead Optimization
1.7.6.3.4 Pharmacovigilance and Safety Monitoring
1.7.6.3.5 Pre-clinical Development
1.7.6.3.6 Manufacturing-Process Optimization
1.7.6.3.7 Other Application
1.7.7 Rest of Asia Pacific
1.7.7.1 Segmentation By End User
1.7.7.1.1 Large Pharmaceutical Companies
1.7.7.1.2 Small and Mid-Size Biotech Firms
1.7.7.1.3 Contract Research Organizations
1.7.7.1.4 Academic and Research Institutes
1.7.7.2 Segmentation By Deployment Mode
1.7.7.2.1 Cloud-Based
1.7.7.2.2 Hybrid
1.7.7.2.3 On-Premise
1.7.7.3 Segmentation By Application
1.7.7.3.1 Clinical-Trial Design and Recruitment
1.7.7.3.2 Drug Discovery and Lead Identification
1.7.7.3.3 Lead Optimization
1.7.7.3.4 Pharmacovigilance and Safety Monitoring
1.7.7.3.5 Pre-clinical Development
1.7.7.3.6 Manufacturing-Process Optimization
1.7.7.3.7 Other Application
Chapter 2. Company Snapshot
2.1 InSilico Medicine
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Numerion Labs, Inc.
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 BenevolentAI Group
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 Shenzhen Jingtai Technology Co., Ltd (XtalPi)
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users
2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Recursion Pharmaceuticals, Inc.
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Deep Genomics Incorporated
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 Schrödinger, LLC
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 Owkin Inc.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 PeptiDream Inc.
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 Healx Limited
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook
Unique Offerings 
